التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand? |
| المؤلفون: |
Shafiekhani, Mojtaba, Shahabinezhad, Farbod, Niknam, Tahmoores, Tara, Seyed Ahmad, Haem, Elham, Mardani, Parviz, Zare, Zahra, Jafarian, Sedigheh, Mirzad Jahromi, Khatereh, Arabsheybani, Sara, Moeini, Yalda Sadat, Alavi, Jalile, Jalali, Seyed Soroush, Salimi, Maryam, Shahriarirad, Reza, Malekhosseini, Seyed Ali |
| المصدر: |
Virology Journal ; volume 18, issue 1 ; ISSN 1743-422X |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2021 |
| مصطلحات موضوعية: |
Infectious Diseases, Virology |
| الوصف: |
Background The management of COVID-19 in organ transplant recipients is among the most imperative, yet less discussed, issues based on their immunocompromised status along with their vast post-transplant medication regimens. No conclusive study has been published to evaluate proper anti-viral and immunomodulator medications effect in treating COVID-19 patients to this date. Method This retrospective study was conducted in Shiraz Transplant Hospital, Iran from March 2020 to May 2021 and included COVID-19 diagnosed patients based on SARS-CoV-2 RT-PCR positive test who had been hospitalized for at least 48 h before enrolling in the study. Clinical and demographic information of patients, along with their treatment course and the medication used were evaluated and analyzed using multiple regression analysis. Results A total of 245 patients with a mean age of 49.59 years were included with a mortality rate of 8.16%. The administration of Remdesivir as an anti-viral drug ( P value < 0.001) and Tocilizumab as an immunomodulator drug ( P value < 0.001) could reduce the hospitalization period in the hospital and the intensive care unit, as well as the mortality rates significantly. Meanwhile, the patients treated with Lopinavir/Ritonavir experienced a lower chance of survival (OR < 1, P value = 0.04). No significant difference was observed between various therapeutic regimens in clinical complications such as bacterial coinfections, cardiovascular and gastrointestinal adverse reactions, and liver or kidney dysfunctions. Conclusion The administration of Remdesivir as an anti-viral and Tocilizumab as an immunomodulatory drug in solid-organ transplant recipients could be promising treatments of choice to manage COVID-19. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1186/s12985-021-01700-2 |
| DOI: |
10.1186/s12985-021-01700-2.pdf |
| DOI: |
10.1186/s12985-021-01700-2/fulltext.html |
| الإتاحة: |
https://doi.org/10.1186/s12985-021-01700-2Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.ED9B4A45 |
| قاعدة البيانات: |
BASE |
